Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2005

View Archived Issues

MN-001 shows a good safety profile in healthy volunteers

Dosing begins in phase I study of CCR5 mAb in HIV patients

StemCells works to lift clinical hold on proposed phase I study of HuCNS-SC

PRX-03140 enters phase Ib studies for Alzheimer's

Theratechnologies plans phase III trials for ThGRF

Rigel completes phase I study of R-406

Adenosine A2A receptor agonist/PDE IV inhibitor combination therapy enhances cardioprotection

Antidepressants inhibit steroid transporters and evoke negative feedback on the HPA axis

Sucampo submits lubiprostone NDA

PTC-124 receives fast track status for cystic fibrosis

Sanofi pasteur's new polio vaccine licensed for use

Yamanouchi and Fujisawa form Astellas Pharma

Antiangiogenic actions of oral lenalidomide in rats

New analgesic agents developed at GSK and Euroceltique

Valentis initiates phase IIb study of VLTS-934 for peripheral arterial disease

Memory nominates new drug candidate MEM-63908

Genentech claims new treatments for immunological disorders

Landmark study evaluates Provacel stem cell product in cardiac patients

Antibacterial CY-403 enters preclinical testing

Chinese launch of Bilive vaccine

4SC concludes phase I studies for SC-12267

GSK discloses novel antiinflammatory glucocorticosteroids

Outline of products under development by MediciNova

FDA approves Asmanex for once daily management of asthma

New data on the anxiolytic effects of pregabalin in patients with GAD

New intravenous formulation of Nexium receives FDA approval

Novo Nordisk receives extended E.U. approvals for diabetes drugs

Studies assess gabapentin in cutaneous, postoperative and neuropathic pain

Lamotrigine efficacy, tolerability examined in painful diabetic neuropathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...